Market Overview

UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity

Related AMRN
UPDATE: What Amarin Would Need To Disclose To Ensure Non-Misleading Speech
First Amendment Decision a Win for Amarin and Physician Plaintiffs

Aegis Capital said on Monday that it initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and a price target of $25.

Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA."

Amarin Corporation closed at $15.12 on Friday.

Latest Ratings for AMRN

Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings


Related Articles (AMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters